Kailera shares fall on nausea rates despite weight-loss trial success
Investors focused on tolerability signals rather than the efficacy result, according to Reuters.
The wire
- 01Reuters reports Kailera's stock tumbled after high nausea rates accompanied a successful weight-loss drug trial readout.
- 02Tolerability is now the main differentiator among incretin and next-generation obesity candidates, shaping which agents prescribers reach for first.
- 03Discontinuation rates and dose-titration data will determine whether the nausea signal is manageable in practice.
From the source
Read at reuters.comKailera shares tumble on high nausea rates despite weight-loss drug's success